| 104.85 Delayed Data As of Sep 13 |  +1.74 / +1.69%Today’s Change | 87.49 Today|||52-Week Range 163.43 | +5.70% Year-to-Date |
| FDA Grants Priority Review to Global Blood's SCD Candidate Sep 06 / Zacks.com - Paid Partner Content |
| Previous close | 103.11 |
| Today’s open | 102.64 |
| Day’s range | 102.19 - 107.36 |
| Volume | 818,615 |
| Average volume (3 months) | 565,136 |
| Market cap | $5.8B |
| Earnings growth (last year) | -38.50% |
| Earnings growth (this year) | -26.44% |
| Earnings growth (next 5 years) | -64.66% |
| Revenue growth (last year) | +54.06% |
| P/E ratio | NM |
| Price/Sales | 94.57 |
| Price/Book | 3.05 |
| Today’s change | Today’s % change | |
|---|---|---|
| MRNAModerna Inc | +0.31 | +1.89% |
| TECHBio-Techne Corp | +1.03 | +0.52% |
| BPMCBlueprint Medicines ... | -0.06 | -0.08% |
| ONCESpark Therapeutics I... | -0.88 | -0.83% |
| Next reporting date | October 30, 2019 |
| EPS forecast (this quarter) | -$3.52 |
| Annual revenue (last year) | $54.6M |
| Annual profit (last year) | -$555.6M |
| Net profit margin | -1,018.02% |
Sector Health Technology |
Industry Biotechnology |
President, Chief Executive Officer & Director Nick Leschly |
Chief Operating & Legal Officer Jason F. Cole |
Corporate headquarters Cambridge, Massachusetts |
